Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Wedge Industrial Co Ltd
SZSE:000534
|
CN |
|
R
|
Rugvista Group AB (publ)
STO:RUG
|
SE |
|
C
|
Cam Resources Bhd
KLSE:CAMRES
|
MY |
Arbutus Biopharma Corp
PP&E Net
Arbutus Biopharma Corp
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
PP&E Net
$32k
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
-37%
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$7.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$3.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$5.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's PP&E Net?
PP&E Net
32k
USD
Based on the financial report for Dec 31, 2025, Arbutus Biopharma Corp's PP&E Net amounts to 32k USD.
What is Arbutus Biopharma Corp's PP&E Net growth rate?
PP&E Net CAGR 10Y
-37%
Over the last year, the PP&E Net growth was -99%. The average annual PP&E Net growth rates for Arbutus Biopharma Corp have been -83% over the past three years , -68% over the past five years , and -37% over the past ten years .
